Breaking News, Financial News

Financial Reports: Sanofi

Diabetes, Genzyme, Generics key drivers

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Sanofi 4Q13 4Q Revenues: €8.5 billion (+7% CER / -1% on a reported basis) 4Q Earnings: €1.0 billion (+172%) FY Revenues: €33.0 billion (-1% CER / -6% on a reported basis) FY Earnings: €3.7 billion (-24%) Comments: Pharma sales rose 8% (all results CER) to €7.0 billion in 4Q, driven by a 19% jump in the Diabetes division (€1.7 billion), a 31% boost from Genzyme (€595 million), and a 12% increase in Generics (€478 million). Vaccine sales were flat for 4Q and FY, at €959 million and €3.7 billi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters